Rates of Hepatocellular Carcinoma After Start of Treatment for Chronic Hepatitis C Remain High with Direct Acting Antivirals: Analysis from a Swiss Liver Transplant Center

BACKGROUND: Direct-acting antivirals (DAA) have revolutionized the therapy of chronic hepatitis C (CHC) and have replaced previous PEG-interferon/ribavirin (PEG-IFN/RBV) treatment. Patients with CHC and advanced liver disease are at increased risk for hepatocellular carcinoma (HCC). However, the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Karbeyaz, Fatih, Kissling, Seraphina, Jaklin, Paul Julius, Bachofner, Jaqueline, Brunner, Barbara, Müllhaupt, Beat, Winder, Thomas, Mertens, Joachim C, Misselwitz, Benjamin, von Felten, Stefanie, Siebenhüner, Alexander R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205644/
https://www.ncbi.nlm.nih.gov/pubmed/34150679
http://dx.doi.org/10.2147/JHC.S289955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205644/
https://www.ncbi.nlm.nih.gov/pubmed/34150679
http://dx.doi.org/10.2147/JHC.S289955

Ejemplares similares